For many lung cancer patients, the best treatment options involve checkpoint inhibitors. These immunotherapy drugs unleash a patient’s immune system against their disease and can yield dramatic results, even in advanced cancers.
But checkpoint inhibitors come with a huge caveat: They only help a small subset of patients. Doctors struggle to predict who these patients are and — just as important — who they aren’t.
Results from a new study published in the journal JCI Insight could help improve those forecasts.